Click here to get full coverage on Sapanisertib Plus Weekly Chemo Improves PFS in Platinum-Resistant Ovarian Cancer - Targeted Oncology

Sapanisertib Plus Weekly Chemo Improves PFS in Platinum-Resistant Ovarian Cancer  Targeted Oncology

Sapanisertib Plus Weekly Chemo Improves PFS in Platinum-Resistant Ovarian Cancer - Targeted Oncology

Click here to get full coverage on CMS lifts claims hold on PFS, other claims amid government shutdown - American Hospital Association

CMS lifts claims hold on PFS, other claims amid government shutdown  American Hospital Association

CMS lifts claims hold on PFS, other claims amid government shutdown - American Hospital Association

Click here to get full coverage on Giredestrant/Everolimus Extends PFS for ER+, HER2- Advanced Breast Cancer - OncLive

Giredestrant/Everolimus Extends PFS for ER+, HER2- Advanced Breast Cancer  OncLive

Giredestrant/Everolimus Extends PFS for ER+, HER2- Advanced Breast Cancer - OncLive

Click here to get full coverage on ESMO 25: OS/PFS Win For RemeGen’s Disitamab Vedotin/Toripalimab Combo In 1L Urothelial Carcinoma - Citeline News & Insights

ESMO 25: OS/PFS Win For RemeGen’s Disitamab Vedotin/Toripalimab Combo In 1L Urothelial Carcinoma  Citeline News & Insights

ESMO 25: OS/PFS Win For RemeGen’s Disitamab Vedotin/Toripalimab Combo In 1L Urothelial Carcinoma - Citeline News & Insights

Click here to get full coverage on Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma - CancerNetwork

Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma  CancerNetwork

Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma - CancerNetwork

Click here to get full coverage on Gedatolisib Prolongs PFS in Advanced Breast Cancer - Medscape

Gedatolisib Prolongs PFS in Advanced Breast Cancer  Medscape

Gedatolisib Prolongs PFS in Advanced Breast Cancer - Medscape

Click here to get full coverage on ASCENT-03: Sacituzumab Govitecan Improves PFS in First-Line Metastatic TNBC - Docwire News

ASCENT-03: Sacituzumab Govitecan Improves PFS in First-Line Metastatic TNBC  Docwire News

ASCENT-03: Sacituzumab Govitecan Improves PFS in First-Line Metastatic TNBC - Docwire News

Click here to get full coverage on Meteoric Resources Advances Caldeira Rare Earth Project with Strong PFS Results and Investor Support - TipRanks

Meteoric Resources Advances Caldeira Rare Earth Project with Strong PFS Results and Investor Support  TipRanks

Meteoric Resources Advances Caldeira Rare Earth Project with Strong PFS Results and Investor Support - TipRanks

Click here to get full coverage on Simultaneous Integrated Boost Radiotherapy Improves PFS in Cervical Cancer - CancerNetwork

Simultaneous Integrated Boost Radiotherapy Improves PFS in Cervical Cancer  CancerNetwork

Simultaneous Integrated Boost Radiotherapy Improves PFS in Cervical Cancer - CancerNetwork

Click here to get full coverage on Camrelizumab Plus Famitinib Extends PFS vs Chemotherapy in First-Line Metastatic Cervical Cancer - OncLive

Camrelizumab Plus Famitinib Extends PFS vs Chemotherapy in First-Line Metastatic Cervical Cancer  OncLive

Camrelizumab Plus Famitinib Extends PFS vs Chemotherapy in First-Line Metastatic Cervical Cancer - OncLive

Click here to get full coverage on Dabrafenib Combo Confers PFS Benefit in RAI-Refractory BRAF V600-Mutant DTC - Targeted Oncology

Dabrafenib Combo Confers PFS Benefit in RAI-Refractory BRAF V600-Mutant DTC  Targeted Oncology

Dabrafenib Combo Confers PFS Benefit in RAI-Refractory BRAF V600-Mutant DTC - Targeted Oncology

Click here to get full coverage on Ivonescimab Combo Boosts PFS in Advanced Squamous NSCLC Trial - CancerNetwork

Ivonescimab Combo Boosts PFS in Advanced Squamous NSCLC Trial  CancerNetwork

Ivonescimab Combo Boosts PFS in Advanced Squamous NSCLC Trial - CancerNetwork

Click here to get full coverage on Sac-TMT Improves PFS in HR+/HER2– Metastatic Breast Cancer - Targeted Oncology

Sac-TMT Improves PFS in HR+/HER2– Metastatic Breast Cancer  Targeted Oncology

Sac-TMT Improves PFS in HR+/HER2– Metastatic Breast Cancer - Targeted Oncology

Click here to get full coverage on Relacorilant Plus Nab-Paclitaxel Yields PFS Advantage in PARP Inhibitor–Exposed PROC - OncLive

Relacorilant Plus Nab-Paclitaxel Yields PFS Advantage in PARP Inhibitor–Exposed PROC  OncLive

Relacorilant Plus Nab-Paclitaxel Yields PFS Advantage in PARP Inhibitor–Exposed PROC - OncLive

Click here to get full coverage on Tiragolumab Regimen Misses PFS End Point in Hepatocellular Carcinoma - CancerNetwork

Tiragolumab Regimen Misses PFS End Point in Hepatocellular Carcinoma  CancerNetwork

Tiragolumab Regimen Misses PFS End Point in Hepatocellular Carcinoma - CancerNetwork

Click here to get full coverage on Tiragolumab/Atezolizumab/Bevacizumab Fails to Significantly Improve PFS in Advanced/Metastatic HCC - OncLive

Tiragolumab/Atezolizumab/Bevacizumab Fails to Significantly Improve PFS in Advanced/Metastatic HCC  OncLive

Tiragolumab/Atezolizumab/Bevacizumab Fails to Significantly Improve PFS in Advanced/Metastatic HCC - OncLive

Click here to get full coverage on CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC - OncLive

CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC  OncLive

CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC - OncLive

Click here to get full coverage on Sac-TMT Yields PFS Benefit Over Chemotherapy in Pretreated HR+, HER2– Metastatic Breast Cancer - OncLive

Sac-TMT Yields PFS Benefit Over Chemotherapy in Pretreated HR+, HER2– Metastatic Breast Cancer  OncLive

Sac-TMT Yields PFS Benefit Over Chemotherapy in Pretreated HR+, HER2– Metastatic Breast Cancer - OncLive

Click here to get full coverage on Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI/ADT Yields Superior PFS in PSMA+ mHSPC - OncLive

Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI/ADT Yields Superior PFS in PSMA+ mHSPC  OncLive

Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI/ADT Yields Superior PFS in PSMA+ mHSPC - OncLive

Click here to get full coverage on RCC: Lenvatinib/Everolimus Extends PFS After PD-1 Inhibition - The ASCO Post

RCC: Lenvatinib/Everolimus Extends PFS After PD-1 Inhibition  The ASCO Post

RCC: Lenvatinib/Everolimus Extends PFS After PD-1 Inhibition - The ASCO Post

Click here to get full coverage on HORIZON-Breast01: SHR-A1811 Shows 3x Longer PFS vs Pyrotinib/Capecitabine in HER2+ Disease - Docwire News

HORIZON-Breast01: SHR-A1811 Shows 3x Longer PFS vs Pyrotinib/Capecitabine in HER2+ Disease  Docwire News

HORIZON-Breast01: SHR-A1811 Shows 3x Longer PFS vs Pyrotinib/Capecitabine in HER2+ Disease - Docwire News

Click here to get full coverage on Inhibrx Biosciences (Nasdaq: INBX) more than doubles median PFS in chondrosarcoma - Stock Titan

Inhibrx Biosciences (Nasdaq: INBX) more than doubles median PFS in chondrosarcoma  Stock Titan

Inhibrx Biosciences (Nasdaq: INBX) more than doubles median PFS in chondrosarcoma - Stock Titan

Click here to get full coverage on Osimertinib Plus Local Consolidative Therapy Significantly Extends PFS in EGFR-Mutant NSCLC - OncLive

Osimertinib Plus Local Consolidative Therapy Significantly Extends PFS in EGFR-Mutant NSCLC  OncLive

Osimertinib Plus Local Consolidative Therapy Significantly Extends PFS in EGFR-Mutant NSCLC - OncLive

Click here to get full coverage on TROPION-Breast02 Data Support Dato-DXd as New First-line SOC in Triple-Negative Breast Cancer - OncLive

TROPION-Breast02 Data Support Dato-DXd as New First-line SOC in Triple-Negative Breast Cancer  OncLive

TROPION-Breast02 Data Support Dato-DXd as New First-line SOC in Triple-Negative Breast Cancer - OncLive

Click here to get full coverage on Pembrolizumab Plus Chemo Boosts PFS, OS in Platinum-Resistant Recurrent Ovarian Cancer: Nicoletta Colombo, MD, PhD - AJMC

Pembrolizumab Plus Chemo Boosts PFS, OS in Platinum-Resistant Recurrent Ovarian Cancer: Nicoletta Colombo, MD, PhD  AJMC

Pembrolizumab Plus Chemo Boosts PFS, OS in Platinum-Resistant Recurrent Ovarian Cancer: Nicoletta Colombo, MD, PhD - AJMC

Click here to get full coverage on ESMO25: Keytruda combo defies doubt, delivers PFS and OS gains in ovarian cancer - Pharmaceutical Technology

ESMO25: Keytruda combo defies doubt, delivers PFS and OS gains in ovarian cancer  Pharmaceutical Technology

ESMO25: Keytruda combo defies doubt, delivers PFS and OS gains in ovarian cancer - Pharmaceutical Technology

Click here to get full coverage on Contemporary RCC trial adds fresh lenvatinib/everolimus PFS perspective - Urology Times

Contemporary RCC trial adds fresh lenvatinib/everolimus PFS perspective  Urology Times

Contemporary RCC trial adds fresh lenvatinib/everolimus PFS perspective - Urology Times

Click here to get full coverage on Fruquintinib Plus Sintilimab Improves PFS in Advanced RCC After First-Line VEGFR TKI Therapy - OncLive

Fruquintinib Plus Sintilimab Improves PFS in Advanced RCC After First-Line VEGFR TKI Therapy  OncLive

Fruquintinib Plus Sintilimab Improves PFS in Advanced RCC After First-Line VEGFR TKI Therapy - OncLive

Click here to get full coverage on PSMAddition at ESMO 2025: ¹⁷⁷Lu-PSMA-617 Plus ADT and ARPI Improves PFS in PSMA-Positive mHSPC - Oncodaily

PSMAddition at ESMO 2025: ¹⁷⁷Lu-PSMA-617 Plus ADT and ARPI Improves PFS in PSMA-Positive mHSPC  Oncodaily

PSMAddition at ESMO 2025: ¹⁷⁷Lu-PSMA-617 Plus ADT and ARPI Improves PFS in PSMA-Positive mHSPC - Oncodaily

Click here to get full coverage on Provident (NYSE: PFS) awards $63,000 in Community Partnership grants to 8 NJ nonprofits - Stock Titan

Provident (NYSE: PFS) awards $63,000 in Community Partnership grants to 8 NJ nonprofits  Stock Titan

Provident (NYSE: PFS) awards $63,000 in Community Partnership grants to 8 NJ nonprofits - Stock Titan

Click here to get full coverage on Dr Mayer Discusses PFS Data From evERA at ESMO 2025 - Targeted Oncology

Dr Mayer Discusses PFS Data From evERA at ESMO 2025  Targeted Oncology

Dr Mayer Discusses PFS Data From evERA at ESMO 2025 - Targeted Oncology

Click here to get full coverage on Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC - CancerNetwork

Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC  CancerNetwork

Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC - CancerNetwork

Click here to get full coverage on Yüksel Ürün: Ivonescimab + Chemo Improves PFS in 1L sq-NSCLC - Oncodaily

Yüksel Ürün: Ivonescimab + Chemo Improves PFS in 1L sq-NSCLC  Oncodaily

Yüksel Ürün: Ivonescimab + Chemo Improves PFS in 1L sq-NSCLC - Oncodaily

Click here to get full coverage on Crinetics (NASDAQ: CRNX) reports 74% PFS for paltusotine; NANETS 2025 abstracts on NETs - Stock Titan

Crinetics (NASDAQ: CRNX) reports 74% PFS for paltusotine; NANETS 2025 abstracts on NETs  Stock Titan

Crinetics (NASDAQ: CRNX) reports 74% PFS for paltusotine; NANETS 2025 abstracts on NETs - Stock Titan

Click here to get full coverage on Delcath’s Chemosat plus ICIs triples PFS in uveal melanoma - BioWorld MedTech

Delcath’s Chemosat plus ICIs triples PFS in uveal melanoma  BioWorld MedTech

Delcath’s Chemosat plus ICIs triples PFS in uveal melanoma - BioWorld MedTech

Click here to get full coverage on HARMONi-6: Ivonescimab+Chemo in Squamous NSCLC - Oncodaily

HARMONi-6: Ivonescimab+Chemo in Squamous NSCLC  Oncodaily

HARMONi-6: Ivonescimab+Chemo in Squamous NSCLC - Oncodaily

Click here to get full coverage on Ivonescimab Combo Improves Progression-Free Survival in Advanced NSCLC - Cure Today

Ivonescimab Combo Improves Progression-Free Survival in Advanced NSCLC  Cure Today

Ivonescimab Combo Improves Progression-Free Survival in Advanced NSCLC - Cure Today

Click here to get full coverage on Akeso, Summit’s PD-1/VEGF Blocker ‘Firmly’ Beats Expectations With Encouraging Survival Data - BioSpace

Akeso, Summit’s PD-1/VEGF Blocker ‘Firmly’ Beats Expectations With Encouraging Survival Data  BioSpace

Akeso, Summit’s PD-1/VEGF Blocker ‘Firmly’ Beats Expectations With Encouraging Survival Data - BioSpace

Click here to get full coverage on Enhertu Plus Perjeta Boosts Survival in HER2-Positive Breast Cancer - Cure Today

Enhertu Plus Perjeta Boosts Survival in HER2-Positive Breast Cancer  Cure Today

Enhertu Plus Perjeta Boosts Survival in HER2-Positive Breast Cancer - Cure Today

Click here to get full coverage on ESMO 25: Akeso’s Ivonescimab Triumphs In 1L Squamous NSCLC, With Longest PFS In China Population - Citeline News & Insights

ESMO 25: Akeso’s Ivonescimab Triumphs In 1L Squamous NSCLC, With Longest PFS In China Population  Citeline News & Insights

ESMO 25: Akeso’s Ivonescimab Triumphs In 1L Squamous NSCLC, With Longest PFS In China Population - Citeline News & Insights

Click here to get full coverage on CROWN Analysis: The Role of ctDNA in Predicting Improved Survival Outcomes in Patients With ALK+ NSCLC - Cancer Nursing Today

CROWN Analysis: The Role of ctDNA in Predicting Improved Survival Outcomes in Patients With ALK+ NSCLC  Cancer Nursing Today

CROWN Analysis: The Role of ctDNA in Predicting Improved Survival Outcomes in Patients With ALK+ NSCLC - Cancer Nursing Today

Click here to get full coverage on ESMO25: Roche shares PFS data backing oral SERD in ESR1m breast cancer - FirstWord Pharma

ESMO25: Roche shares PFS data backing oral SERD in ESR1m breast cancer  FirstWord Pharma

ESMO25: Roche shares PFS data backing oral SERD in ESR1m breast cancer - FirstWord Pharma

Click here to get full coverage on Trodelvy in Metastatic Triple-Negative Breast Cancer Supported by Phase 3 Trial - Cure Today

Trodelvy in Metastatic Triple-Negative Breast Cancer Supported by Phase 3 Trial  Cure Today

Trodelvy in Metastatic Triple-Negative Breast Cancer Supported by Phase 3 Trial - Cure Today

Click here to get full coverage on Ibrutinib Plus Rituximab Shows PFS Benefit Over Chemoimmunotherapy in Untreated MCL - OncLive

Ibrutinib Plus Rituximab Shows PFS Benefit Over Chemoimmunotherapy in Untreated MCL  OncLive

Ibrutinib Plus Rituximab Shows PFS Benefit Over Chemoimmunotherapy in Untreated MCL - OncLive

Click here to get full coverage on Tucatinib Shows Improvement in PFS in Patients with HER2+ Metastatic Breast Cancer - Targeted Oncology

Tucatinib Shows Improvement in PFS in Patients with HER2+ Metastatic Breast Cancer  Targeted Oncology

Tucatinib Shows Improvement in PFS in Patients with HER2+ Metastatic Breast Cancer - Targeted Oncology

Click here to get full coverage on ESMO 2025: Hutchmed’s VEGF plus Innovent’s PD-1 inhibitor bolsters PFS in RCC - Clinical Trials Arena

ESMO 2025: Hutchmed’s VEGF plus Innovent’s PD-1 inhibitor bolsters PFS in RCC  Clinical Trials Arena

ESMO 2025: Hutchmed’s VEGF plus Innovent’s PD-1 inhibitor bolsters PFS in RCC - Clinical Trials Arena

Click here to get full coverage on Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer - CancerNetwork

Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer  CancerNetwork

Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer - CancerNetwork

Click here to get full coverage on Tucatinib Plus Trastuzumab and Pertuzumab Maintenance Improves PFS in HER2+ Metastatic Breast Cancer - OncLive

Tucatinib Plus Trastuzumab and Pertuzumab Maintenance Improves PFS in HER2+ Metastatic Breast Cancer  OncLive

Tucatinib Plus Trastuzumab and Pertuzumab Maintenance Improves PFS in HER2+ Metastatic Breast Cancer - OncLive

Click here to get full coverage on ESMO: Akeso, Summit's ivonescimab beats PD-1 in first chemo combo win in 1st-line NSCLC - Fierce Pharma

ESMO: Akeso, Summit's ivonescimab beats PD-1 in first chemo combo win in 1st-line NSCLC  Fierce Pharma

ESMO: Akeso, Summit's ivonescimab beats PD-1 in first chemo combo win in 1st-line NSCLC - Fierce Pharma

Click here to get full coverage on Fruquintinib Combo Prolongs PFS in Advanced/Metastatic RCC - CancerNetwork

Fruquintinib Combo Prolongs PFS in Advanced/Metastatic RCC  CancerNetwork

Fruquintinib Combo Prolongs PFS in Advanced/Metastatic RCC - CancerNetwork

Click here to get full coverage on 4.5 vs 2.5 mo PFS by NLR — BriaCell Phase 3 biomarker data at ESMO 2025; pooled 113 pts - Stock Titan

4.5 vs 2.5 mo PFS by NLR — BriaCell Phase 3 biomarker data at ESMO 2025; pooled 113 pts  Stock Titan

4.5 vs 2.5 mo PFS by NLR — BriaCell Phase 3 biomarker data at ESMO 2025; pooled 113 pts - Stock Titan

Click here to get full coverage on Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer - CancerNetwork

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer  CancerNetwork

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer - CancerNetwork

Click here to get full coverage on CMS Releases CY 26 PFS Proposed Rule - Michigan Health & Hospital Association

CMS Releases CY 26 PFS Proposed Rule  Michigan Health & Hospital Association

CMS Releases CY 26 PFS Proposed Rule - Michigan Health & Hospital Association

Click here to get full coverage on Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL - OncLive

Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL  OncLive

Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL - OncLive

Click here to get full coverage on Liquidity Mapping Around (PFS) Price Events - news.stocktradersdaily.com

Liquidity Mapping Around (PFS) Price Events  news.stocktradersdaily.com

Liquidity Mapping Around (PFS) Price Events - news.stocktradersdaily.com

Click here to get full coverage on HER2CLIMB-05: Tucatinib Addition to Standard Maintenance Significantly Extends PFS in HER2+ mBC - Docwire News

HER2CLIMB-05: Tucatinib Addition to Standard Maintenance Significantly Extends PFS in HER2+ mBC  Docwire News

HER2CLIMB-05: Tucatinib Addition to Standard Maintenance Significantly Extends PFS in HER2+ mBC - Docwire News

Click here to get full coverage on Summit Therapeutics Plans BLA; Ivonescimab Cuts PFS Risk 48% | SMMT Stock News - Stock Titan

Summit Therapeutics Plans BLA; Ivonescimab Cuts PFS Risk 48% | SMMT Stock News  Stock Titan

Summit Therapeutics Plans BLA; Ivonescimab Cuts PFS Risk 48% | SMMT Stock News - Stock Titan

Click here to get full coverage on Subcutaneous Daratumumab Improves PFS in Smoldering Multiple Myeloma - CancerNetwork

Subcutaneous Daratumumab Improves PFS in Smoldering Multiple Myeloma  CancerNetwork

Subcutaneous Daratumumab Improves PFS in Smoldering Multiple Myeloma - CancerNetwork

Click here to get full coverage on First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC - OncLive

First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC  OncLive

First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC - OncLive

Click here to get full coverage on AstraZeneca, Daiichi’s Datroway demonstrated significant improvement in OS, PFS - TipRanks

AstraZeneca, Daiichi’s Datroway demonstrated significant improvement in OS, PFS  TipRanks

AstraZeneca, Daiichi’s Datroway demonstrated significant improvement in OS, PFS - TipRanks

Click here to get full coverage on 2025 PFS Philadelphia Film Festival, October 16-26 - 6abc Philadelphia

2025 PFS Philadelphia Film Festival, October 16-26  6abc Philadelphia

2025 PFS Philadelphia Film Festival, October 16-26 - 6abc Philadelphia

Click here to get full coverage on Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma - OncLive

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma  OncLive

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma - OncLive

Click here to get full coverage on KENTRO PARTNERS WITH THE PFS TEAM ON THE VA INTEGRATED HEALTHCARE TRANSFORMATION 2.0 CONTRACT - PR Newswire

KENTRO PARTNERS WITH THE PFS TEAM ON THE VA INTEGRATED HEALTHCARE TRANSFORMATION 2.0 CONTRACT  PR Newswire

KENTRO PARTNERS WITH THE PFS TEAM ON THE VA INTEGRATED HEALTHCARE TRANSFORMATION 2.0 CONTRACT - PR Newswire

Click here to get full coverage on 14.6‑month median PFS — Celcuity's PIK3CA mutant cohort fully enrolled; topline trial data due 2026 - Stock Titan

14.6‑month median PFS — Celcuity's PIK3CA mutant cohort fully enrolled; topline trial data due 2026  Stock Titan

14.6‑month median PFS — Celcuity's PIK3CA mutant cohort fully enrolled; topline trial data due 2026 - Stock Titan

Click here to get full coverage on Pumitamig Shows Positive Trend in PFS Treating Patients With ES-SCLC - Pharmacy Times

Pumitamig Shows Positive Trend in PFS Treating Patients With ES-SCLC  Pharmacy Times

Pumitamig Shows Positive Trend in PFS Treating Patients With ES-SCLC - Pharmacy Times

Click here to get full coverage on On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC - OncLive

On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC  OncLive

On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC - OncLive

Click here to get full coverage on Efficiency Adjustment Explainer | 2026 Medicare PFS Proposed Rule - American College of Cardiology

Efficiency Adjustment Explainer | 2026 Medicare PFS Proposed Rule  American College of Cardiology

PFS

Price Chart

Key Statistics

Technicals

About PFS

Latest News

Sapanisertib Plus Weekly Chemo Improves PFS in Platinum-Resistant Ovarian Cancer - Targeted Oncology

CMS lifts claims hold on PFS, other claims amid government shutdown - American Hospital Association

Giredestrant/Everolimus Extends PFS for ER+, HER2- Advanced Breast Cancer - OncLive

Advanced Charts

Top Gainers

Top Losers